Goldman Sachs Upgrades Genmab A/S to Buy on Positive 2026 Outlook
Goldman Sachs upgraded Genmab A/S (GMAB) to Buy with a price target of $30.50, citing strong 2026 catalysts from its pipeline assets. The firm highlighted combined peak sales potential exceeding $5 billion from Epkinly, Rina-S, and petosemtamab, despite concerns over declining Darzalex royalty revenues starting in 2029.
Topics: analyst upgrade biotech Genmab A/S Goldman Sachs stock rating